Otsuka Holdings Co ( (OTSKF) ) has released its Q3 earnings. Here is a breakdown of the information Otsuka Holdings Co presented to its investors.
Otsuka Holdings Co., Ltd. is a leading healthcare company based in Japan, operating primarily in the pharmaceutical and nutraceutical sectors, and is recognized for its innovations in total healthcare solutions.
In its latest earnings report for the nine-month period ending September 30, 2024, Otsuka Holdings Co., Ltd. demonstrated robust financial growth with a significant increase in revenue and profit across its core business segments, despite certain challenges.
The company reported a 17% year-on-year increase in revenue, reaching ¥1,730,076 million, driven primarily by strong sales in its pharmaceutical and nutraceutical sectors. Key products such as antipsychotic agents REXULTI and ABILIFY MAINTENA, as well as the anti-cancer agent LONSURF, significantly contributed to this growth. Meanwhile, the nutraceutical division saw notable gains with products like POCARI SWEAT and Nature Made supplements. Operating profit rose by 28.8% to ¥261,045 million, while profit attributable to owners increased by 18.5% to ¥191,672 million.
Strategically, Otsuka Holdings expanded its portfolio through the acquisition of Jnana Therapeutics Inc. and continued its investment in research and development, with a focus on areas such as psychiatry, neurology, and oncology. Despite an increase in impairment losses, the company managed to enhance its business profits through revenue growth and efficient cost management.
Looking ahead, Otsuka Holdings maintains a positive outlook for the fiscal year ending December 31, 2024, with expectations of continued growth in revenue and business profit, supported by its strategic initiatives and strong market presence in key healthcare areas.
